Intranasal nanoformulations of ketamine and sertraline: Comparative insights into combined protective antidepressant effect
Authors:
- Abdelrahman M. EldawenyAEAbdelrahman M. Eldaweny
- Sarah YahiaSYSarah Yahia
- Rabab H. SayedRSRabab H. Sayed
- Aya I. AbdelazizAAAya I. Abdelaziz
- Ibrahim M. El-SherbinyIEIbrahim M. El-Sherbiny
- 8 June 2026
- journal article
- Published by Elsevier in Journal of Drug Delivery Science and Technology
- Vol. 124
Abstract
No abstract availableFunding Information
- Science and Technology Development Fund
This publication has 84 references indexed in Scilit:
- Nanonizing bioactives: precision chemistry for next-gen therapeuticsDiscover Materials, 2026
- Dynamic light scattering: a practical guide and applications in biomedical sciencesBiophysical Reviews, 2016
- A Randomized Controlled Trial of Intranasal Ketamine in Major Depressive DisorderBiological Psychiatry, 2014
- Protective effects of phosphodiesterase 2 inhibitor on depression- and anxiety-like behaviors: Involvement of antioxidant and anti-apoptotic mechanismsBehavioural Brain Research, 2014
- Neuropathology of stressActa Neuropathologica, 2013
- Repeated Ketamine Exposure Induces an Enduring Resilient Phenotype in Adolescent and Adult RatsBiological Psychiatry, 2013
- Nasal drug delivery devices: characteristics and performance in a clinical perspective—a reviewDrug Delivery and Translational Research, 2012
- Antioxidant effects of estradiol and 2-hydroxyestradiol on iron-induced lipid peroxidation of rat liver microsomesSteroids, 1994
- [18] Determination of superoxide dismutase activity by purely chemical system based on NAD(P)H oOxidation1990
- A simple equation for description of solute release II. Fickian and anomalous release from swellable devicesJournal of Controlled Release, 1987